The effects of oophorectomy on skeletal metabolism

Mazzuoli, G. F.; Minisola, Salvatore; Bianchi, Giuseppe; Pacitti, M. T.; Rosso, R.; Romagnoli, Elisabetta; Carnevale, Vincenzo; Scarnecchia, L.; Cell, F.S.; Ortore, V.; Carenza, L

doi:10.1016/0960-0760(90)90498-a

Cited by 12 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone turnover has previously been documented following OVX 25,27,30,38–41 . Our results are consistent with these data.…”

Section: Discussionsupporting

confidence: 93%

“…The excretion of calcium, although not as quick to change nor quite as sensitive as NTx, showed similar results. Bone formation indicators, as also documented in this study, have previously been shown to rise more slowly following premenopausal OVX than the bone resorption markers 38–40 …”

Section: Discussionsupporting

confidence: 72%

“…They differ in that none have been obtained as early following surgery and in the use of newer bone resorption markers. Stepan et al and others 25,27,30,38–41 have shown that various markers of bone resorption are significantly increased by 3 months after OVX. Of the bone resorption markers, N‐telopeptide appears to be more sensitive to the differing effects of the two hormones than the pyridinolines and is the most strongly related to early bone change in most regions.…”

Section: Discussionmentioning

confidence: 95%

See 2 more Smart Citations

Premenopausal Ovariectomy-Related Bone Loss: A Randomized, Double-Blind, One-Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate

Prior

Vigna

Wark

et al. 1997

Journal of Bone and Mineral Research

107

View full text Add to dashboard Cite

The purpose of this study was to contrast the effects of conventional estrogen treatment with medroxyprogesterone on cancellous and cortical bone change in the first year following premenopausal ovariectomy. This 1-year double-blind randomized therapy trial was stratified by osteoporosis family history and performed in an academic medical center and community hospitals. Premenopausal women 45 ؎ 5 years old, postovariectomy for benign diseases were provided 600 mg/day of calcium and randomized to daily therapy with conjugated equine estrogen (CEE, 0.6 mg) or medroxyprogesterone (MPA, 10 mg). The primary outcome variable was spinal quantitative computed tomography (QCT) bone density change over 1 year with additional outcomes of dual-energy X-ray absorptiometry (DXA) of proximal femur (FN), whole body (WB), and spine segment (WBS) and N-telopeptide, bone-specific alkaline phosphatase, and other bone marker, hormonal, and weight changes. Results in the 33 women completing the study, whose initial bone densities were normal (QCT 133 mg/cm 3 , femoral neck 0.94 g/cm 2 , whole body DXA 1.13 g/cm 2 ), showed annual QCT loss during CEE therapy of ؊11.5 mg/cm 3 ( p < 0.0007) and MPA bone loss of ؊19.7 mg/cm 3 ( p < 0.0001). Losses were marginally greater on MPA than CEE ( p ‫؍‬ 0.04). Extremely high postovariectomy (5 days) and pretreatment resorption markers (>3 SD above premenopausal normal levels) were significantly related to bone loss. Across the year, resorption decreased during CEE but increased on MPA treatment. Significant DXA bone losses were prevented by CEE treatment (؊1.4% FN, ؊.4% WB, and ؊1.5% WBS, all NS). However, DXA bone loss was not prevented by MPA treatment (؊5% FN, ؊2.8% WB, and ؊6.1% WBS, all p < 0.03). Average weight gain was significant (؉3.2 ؎ 4.0 kg) and greater on CEE than MPA (؉4.7 vs. ؉2.0 kg, p ‫؍‬ 0.049). In conclusion, CEE therapy did not prevent significant 8% cancellous spinal bone loss in the first year following premenopausal ovariectomy, despite supplementation with 600 mg/day of calcium, good control of vasomotor symptoms, and nearly 5 kg of gain in weight. Significant DXA bone loss, however, was prevented by CEE, but not by MPA therapy. These unexpected results were statistically related to high bone resorption following ovariectomy, which CEE suppressed but MPA did not. Bone formation markers increased during MPA therapy but were unchanged during CEE

show abstract

“…Bone turnover has previously been documented following OVX 25,27,30,38–41 . Our results are consistent with these data.…”

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Premenopausal Ovariectomy-Related Bone Loss: A Randomized, Double-Blind, One-Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate

Prior

Vigna

Wark

et al. 1997

Journal of Bone and Mineral Research

107

View full text Add to dashboard Cite

show abstract

“…[10][11][12][13][14] There is a strong positive association between serum or urinary estrogen levels and bone mineral density in premenopausal and postmenopausal women, and the skeletal effects of low levels of estrogens are clearly seen after menopause or removal of the ovaries. [37][38][39][40][41][42][43][44][45][46] In addition, women who have been receiving estrogen-replacement therapy, especially long-term estrogen users, have significantly higher bone mineral *For each variable, the rate ratios have been adjusted for all the other variables listed in the second footnote to Table 3. †Data were missing for some women.…”

Section: Discussionmentioning

confidence: 99%

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Oestrogen loss by surgical ovariectomy or from natural menopause results in accelerated bone loss in both humans and animals [13][14][15]. As a result, oestrogen replacement in both perimenopausal and post-menopausal women has become a mainstay of therapy in women to maintain bone mass and decrease the Abbreviations used : CAT, chloramphenicol acetyltransferase ; CMFH, Ca 2 + /Mg 2 + -free Hepes ; CV, coefficient of variance ; DMEM, Dulbecco's modified Eagle's medium ; EIA, enzyme immunoassay ; ER, oestrogen receptor ; ERE, oestrogen-responsive element ; FBS, fetal bovine serum ; tk, thymidylate kinase.…”

Section: Introductionmentioning

confidence: 99%

Age-related changes in human oestrogen receptor α function and levels in osteoblasts

Ankrom

Patterson

d'AVIS

et al. 1998

Biochemical Journal

View full text Add to dashboard Cite

Oestrogen receptors (ERs) are present in human osteoblasts and mediate anti-resorptive effects on bone. Human osteoblast-like cells derived from different aged healthy female donors not on hormone replacement therapy were utilized under well-defined conditions in vitro to investigate ER function and levels. Treatment with 0.1 nM oestradiol-17beta of cell strains derived from eight young women (less than 50 years of age) increased hydroxyproline levels significantly [an average (2.2+/-0.1 S.E.M.)-fold increase], whereas cells derived from nine older women (more than 50 years of age) were not significantly affected. Similarly, cell strains, derived from younger women, transfected with a consensus oestrogen-responsive element linked to chloramphenicol acetyltransferase exhibited a greater response to oestrogen than strains derived from older women. When basal ERalpha levels were measured by enzyme immunoassay and normalized on a per cell basis, osteoblast-like strains derived from younger women (n=24) had a mean value of 2.54+/-0.16 fmol of ERalpha per 10(6) cells. In contrast, strains derived from older women (n=20) had a mean value of 5.44+/-0.48 fmol of ERalpha per 10(6) cells. An age-related increase in ERalpha number was also observed in human skin-derived fibroblasts and directly in dermal biopsies from women not on hormone replacement therapy. The results demonstrate ligand concentration-dependent ERalpha induction and indicate a loss of receptor regulation and diminution of ligand-receptor signal transduction with increasing donor age.

show abstract

The effects of oophorectomy on skeletal metabolism

Cited by 12 publications

References 6 publications

Premenopausal Ovariectomy-Related Bone Loss: A Randomized, Double-Blind, One-Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate

Premenopausal Ovariectomy-Related Bone Loss: A Randomized, Double-Blind, One-Year Trial of Conjugated Estrogen or Medroxyprogesterone Acetate

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

Age-related changes in human oestrogen receptor α function and levels in osteoblasts

Contact Info

Product

Resources

About